RxDoctor Payments DataLook up a doctor →

Scott Anderson, DO

Family Medicine · Hot Springs, ARNPI 1366403479

Payments from drug & device makers

$15,176in general payments, 2019–2025

Across 1,023 payments — averaging $14.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • Amgen$2K
  • AbbVie$2K
  • Pfizer$1K
  • GSK$995
  • Lilly USA, LLC$953
  • plus $7K from 51 others

What the payments were for

  • Food & beverage$14,99699%
  • Education$1801%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca105$1,858
Amgen(2 entities)122$1,777
AbbVie(2 entities)121$1,509
Pfizer110$1,371
GSK76$995
Lilly USA, LLC78$953
Novo Nordisk60$835
Antares Pharma, Inc.29$576
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC28$422
Boehringer Ingelheim24$361
Takeda Pharmaceuticals U.S.A., Inc.20$355
Amarin Pharma, Inc.20$322
Exact Sciences19$319
Astellas Pharma US Inc10$316
Novartis21$291
Dexcom, Inc.16$263
Kowa Pharmaceuticals America, Inc.17$215
Abbott11$207
Johnson & Johnson12$186
Biohaven Pharmaceuticals, Inc.9$156
Biohaven Pharmaceutical Holding Company Ltd.7$148
Esperion Therapeutics, Inc.8$125
Sanofi-aventis U.S. LLC9$124
Radius Health, Inc.8$121
Nestle Healthcare Nutrition Inc.5$105
Halozyme Inc5$87
Merck6$77
Supernus Pharmaceuticals, Inc.4$76
Lundbeck LLC5$75
Teva Pharmaceuticals USA, Inc.5$71
Eisai Inc.5$71
Sumitomo Pharma America, Inc.4$62
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)3$61
Almatica Pharma LLC3$59
Gilead3$56
Axsome Therapeutics, Inc.2$55
Genentech USA, Inc.4$52
Regeneron Healthcare Solutions, Inc.3$51
Sunovion Pharmaceuticals Inc.3$37
Seqirus USA Inc2$37
Medline Industries LP1$37
Mylan Specialty L.p.2$33
Viatris Specialty LLC2$32
Idorsia Pharmaceuticals US Inc2$26
Ironwood Pharmaceuticals, Inc2$24
Biomerieux Inc1$20
Bardy Diagnostics, Inc.1$20
Sanofi Pasteur Inc.1$18
Redhill Biopharma Inc.1$17
Acella Pharmaceuticals, LLC1$17
Adlon Therapeutics L.p.1$16
Nevro Corp.1$16
Shield Therapeutics Inc1$14
ARS Pharmaceuticals Operations, Inc.1$14
E.r. Squibb & Sons, L.L.C.1$13
Otsuka America Pharmaceutical, Inc.1$13
Arbor Pharmaceuticals, Inc.1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,176 in reported general payments places this provider in the 95th percentile of 1,347 family medicine providers in Arkansas.

See all family medicine providers in Arkansas

Medicare billing

Part B allowed, 2024
$514,604
Medicare patients
702
Services billed
14,453

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide239$268,668
EliquisApixaban213$166,122
JardianceEmpagliflozin171$141,999
FarxigaDapagliflozin Propanediol132$122,095
MounjaroTirzepatide105$120,823
Repatha SureclickEvolocumab80$96,269
Humira(Cf) PenAdalimumab13$89,575
Praluent PenAlirocumab66$61,145
TrulicityDulaglutide41$46,008
Trelegy ElliptaFluticasone/Umeclidin/Vilanter64$40,691
RybelsusSemaglutide18$32,636
EntrestoSacubitril/Valsartan29$31,981
LinzessLinaclotide36$23,866
MyrbetriqMirabegron45$20,893
XareltoRivaroxaban27$19,896

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$835$301,305257 claims
PfizerEliquis, Premarin, Paxlovid$1,371$181,082309 claims
Lilly USA, LLCMounjaro, Trulicity$953$166,831146 claims
Boehringer IngelheimJardiance, Synjardy$361$159,027190 claims
AstraZenecaFarxiga, Breztri Aerosphere$1,858$132,878150 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta$995$68,878124 claims
NovartisEntresto$291$31,98129 claims
AbbVieLinzess, Synthroid$1,509$31,095174 claims
Astellas Pharma US IncMyrbetriq$316$20,89345 claims
Johnson & JohnsonXarelto$186$19,89627 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$124$19,41025 claims
MerckJanuvia$77$16,80116 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,347 family medicine providers in Arkansas.

Other family medicine in Hot Springs

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →